Journal article 384 views 38 downloads
The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer
,
Julia Lowin,
Berni Sewell ,
Rachel Gemine,
Sarah Rees ,
Kirsty Lanyon ,
Keir Lewis
Value in Health, Volume: 26, Issue: 8, Pages: 1192 - 1200
Swansea University Authors:
Mari Jones , Julia Lowin, Berni Sewell , Rachel Gemine, Sarah Rees , Kirsty Lanyon , Keir Lewis
-
PDF | Version of Record
c. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Download (787.42KB)
DOI (Published version): 10.1016/j.jval.2023.03.2429
Abstract
Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients agai...
| Published in: | Value in Health |
|---|---|
| ISSN: | 1098-3015 |
| Published: |
Elsevier BV
2023
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa63282 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Stopping smoking has proven benefits in nearly all illnesses but the impact and health economic benefits of stopping smoking following a diagnosis of lung cancer are less well defined. We assessed the cost-effectiveness of smoking cessation (SC) services for newly diagnosed lung cancer patients against current usual care, where patients are unlikely to receive SC service referral. A health economic model was constructed in Excel. The modelled population comprised patients with a new diagnosis of non-small-cell lung cancer (NSCLC). Data from the LungCast dataset (Clinical Trials Identifier NCT01192256) were used to estimate model inputs. A structured search of published literature identified inputs not represented in LungCast, including healthcare resource use and costs. Costs were estimated from a 2020/21 UK NHS and Personal Social Services (PSS) perspective. The model estimated the incremental quality-adjusted adjusted life year (QALY) gained in newly diagnosed NSCLC patients receiving targeted SC intervention compared to those receiving no intervention. Extensive one-way sensitivity analyses (SA) explored input and dataset uncertainty.Results: In the five-year base-case, the model estimated an incremental cost of £14,904 per QALY gained through SC intervention. Sensitivity analysis estimated an outcome range of between £9,935 and £32,246 per QALY gained. The model was most sensitive to the estimates of relative quit rates and expected healthcare resource use. |
|---|---|
| Keywords: |
cost, economic model, non–small cell lung cancer, quality-adjusted life-year, smoking cessation |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
8 |
| Start Page: |
1192 |
| End Page: |
1200 |